2023-2024 BIO Executive Committee is Accomplished, Energetic and Diverse Boston, Mass. (June 5, 2023) – Biotechnology Innovation Organization (BIO) is proud to announce its newly elected Executive Committee Directors following Board elections that took place Monday, June 5, during the 2023 BIO International Convention in Boston, June 5-8, 2023. Dr. Ted W. Love, former President & CEO of Global Blood Therapeutics (GBT), will be BIO’s new Chair of its Board of Directors for a two-year term (2023-2025). In addition, BIO today announces the election of its Executive Committee, representing an accomplished group of executives from both emerging, early to mid-stage companies and established, commercial BIO member companies.  Incoming Chair Dr. Ted Love is a distinguished industry leader with more than two decades of management experience, along with nearly a decade of prior experience as a practicing physician. Dr. Love has spent much of his career focused on addressing the ongoing healthcare disparities facing the sickle cell disease community, and leading the development of therapies for this underserved patient population.  He has been a longstanding BIO board director, and most recently has served over the last four years as Chair of the Emerging Companies Section Governing Board, and Vice Chair of BIO’s Health Section Governing Board. “BIO is thrilled to welcome Ted as our new Board Chair,” says Rachel King, BIO President & CEO. “Ted is a proven innovator who has developed and brought critical therapies to market. He embodies the industry’s mission to advance innovation, increase access to novel treatments, and build an inclusive workforce to reach our most underserved patient communities.” “I am excited to lead BIO and the individuals elected today as we usher in a new era for the biotechnology industry,” says Love. “Throughout my career, I’ve seen what it means when people cannot access the care they need. Greater diversity in our industry…

The following statement may be attributed to Nancy Travis, vice president for international affairs, BIO. “The Biotechnology Innovation Organization supports the decision, announced today, by the Office of the U.S. Trade Representative to request formal consultations with Mexico under the U.S. – Mexico – Canada Agreement (USMCA) dispute settlement provisions to resolve Mexico’s treatment of agricultural biotechnology products. “BIO thanks U.S. Trade Representative Ambassador Katherine Tai for taking this action today and all the USTR and USDA officials for their diligent work throughout the technical consultations phase. Unfortunately, technical consultations have not resolved the issue. Mexico’s non-science-based rejection of applications for biotech traits and its ban on imports of biotech corn for human consumption violate the terms of the USMCA and cannot stand. “In addition, as we’ve said all along, Mexico’s stance against biotech corn is bad for Mexico’s consumers, who will face worse food price inflation if the ban is not lifted and is damaging to efforts to address climate concerns through agricultural innovation. BIO has urged the Biden Administration to engage in the dispute resolution process without delay, and we applaud the action USTR is taking today. “It is BIO’s hope that the consultations will resolve this matter and return Mexico to a science-based, transparent and predictable regulatory pathway for innovative agricultural products.”